- Home
- EFC vs IOVA Comparison
EFC vs IOVA Comparison
Compare EFC & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EFC
- IOVA
- Stock Information
- Founded
- EFC 2007
- IOVA 2007
- Country
- EFC United States
- IOVA United States
- Employees
- EFC N/A
- IOVA N/A
- Industry
- EFC Real Estate
- IOVA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- EFC Finance
- IOVA Health Care
- Exchange
- EFC Nasdaq
- IOVA Nasdaq
- Market Cap
- EFC N/A
- IOVA 1.0B
- IPO Year
- EFC 2010
- IOVA N/A
- Fundamental
- Price
- EFC $12.94
- IOVA $3.17
- Analyst Decision
- EFC Buy
- IOVA Strong Buy
- Analyst Count
- EFC 3
- IOVA 9
- Target Price
- EFC $14.17
- IOVA $18.22
- AVG Volume (30 Days)
- EFC 958.6K
- IOVA 9.3M
- Earning Date
- EFC 05-07-2025
- IOVA 05-08-2025
- Dividend Yield
- EFC 12.06%
- IOVA N/A
- EPS Growth
- EFC 105.71
- IOVA N/A
- EPS
- EFC 1.38
- IOVA N/A
- Revenue
- EFC $311,654,000.00
- IOVA $164,070,000.00
- Revenue This Year
- EFC N/A
- IOVA $182.20
- Revenue Next Year
- EFC $9.66
- IOVA $62.10
- P/E Ratio
- EFC $9.36
- IOVA N/A
- Revenue Growth
- EFC 26.18
- IOVA 13698.99
- 52 Week Low
- EFC $11.12
- IOVA $2.70
- 52 Week High
- EFC $14.40
- IOVA $13.60
- Technical
- Relative Strength Index (RSI)
- EFC 54.23
- IOVA 43.38
- Support Level
- EFC $12.73
- IOVA $3.02
- Resistance Level
- EFC $13.16
- IOVA $3.73
- Average True Range (ATR)
- EFC 0.24
- IOVA 0.25
- MACD
- EFC 0.05
- IOVA 0.01
- Stochastic Oscillator
- EFC 75.89
- IOVA 25.33
About IOVA Iovance Biotherapeutics Inc.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.